Amanda Adler
|
Dr. Adler is a Consultant Physician at Addenbrooke's Hospital, Cambridge, and the standing Chair of a Technology Appraisal Committee at the National Institute for Health and Care Excellence (NICE) which addresses new treatments in all disease areas. She trained in economics, medicine, epidemiology, pharmacoepidemiology and pharmacovigilance. Her current clinical work includes diabetes and general medicine in the out-patient, in-patient and community settings. She chaired the NICE Clinical Guidelines for Newer Agents for Type 2 Diabetes and the Quality Standard for Diabetes. Previously for Oxford University, she was the Clinical Epidemiologist for the UK Prospective Diabetes Study (UKPDS). She has worked on projects that set priorities under universal health coverage in countries with low to medium resources in collaboration with NICE International, the World Health Organization, the World Bank, and the Gates Foundation. She serves on the Cardiovascular, Diabetes, Renal, Respiratory and Allergy Expert Advisory Group for the UK Commission on Human Medicines and chaired the Expert Group on the Safety of Insulin for the UK’s Medicines and Health Products Regulatory Agency. Dr. Adler collaborates with the Medical Research Council (MRC) Clinical Trials Unit (London).
|
Stephan Bakker
|
Prof. Bakker (1963) received his MD in Leiden in 1988. Training for registration as an internist-nephrologist was from 1989 to 1995 in Eindhoven and Maastricht. From 1995 to 1999 he was staff member of the department of internal medicine at the Vrije Universiteit Medical Center in Amsterdam. Since 1999, he is staff member of the department of Internal Medicine of the University Medical Center Groningen (UMCG). In 2002, he defended his PhD thesis entitled “Pathophysiology of the Insulin Resistance Syndrome”, in which he proposed an important role for mitochondrial dysfunction and micronutrient deficiency in the deterioration of glucose homeostasis. After this, his research focus shifted from mitochondrial dysfunction towards the discovery and application of biomarkers for nutrition and health in cohort and intervention studies in patient groups (particularly transplantation and diabetes) and the general population. In this field, he is a prime advocate of the use of 24h urine collections for nutritional and health monitoring, with recognition of the strong prognostic impact of 24h urinary creatinine excretion as a marker of muscle mass as one of his main achievements. He is program leader of the Groningen Institute for Organ Transplantation, Prinicipal Investigator of the TransplantLines Biobank and Cohort Study and head of the laboratory and biobank of the large epidemiological PREVEND study in 8,500 subjects of the general population. In February 2014 he was appointed as Professor of Internal Medicine, in particular “A Systems Medicine approach of the Metabolic Syndrome”. He has been author on more than 450 papers in international peer-reviewed journals.
|
Matt Breyer
|
Matthew D. Breyer, MD, CSO BioTDR Lead Generation Eli Lilly & Company: Dr. Breyer received his M.D from Harvard, Internal medicine Residency at Michael Reese Hospital, and training in Nephrology at Parkland Univ Texas Health science center Dallas. From 1985-2007 he was Professor of Medicine in the division of Nephrology at Vanderbilt University Medical Center where his work focused on the study of transgenic mouse models to study diabetic kidney disease and hypertension. Dr. Breyer held numerous NIH and VA awards and from 2001-2006 headed the nephropathy sub-group of the NIH Animal Models of Diabetic Complications Consortium (AMDCC). As a result of his interest in developing treatments for diabetic nephropathy he moved to Eli Lilly in 2007 to oversee a program to develop bio-therapeutics for diabetic kidney disease. In 2009 he was appointed to his current position at Eli Lilly as Chief Scientific Officer Lead Generation Biotechnology Discovery Research, where he oversees preclinical target identification and validation of biologics for metabolic, neurologic, oncologic and chronic kidney diseases.
|
Mark Cooper
|
Mark Cooper is the inaugural Head of the Department of Diabetes, Central Clinical School, Monash University.
He was previously the Chief Scientific Officer of the Baker IDI Heart & Diabetes Institute as well as the Director of the Juvenile Diabetes Research Foundation Centre(JDRF) for Diabetes Complications. He is a trained endocrinologist with an appointment at the co-located Alfred Hospital. Dr Cooper studied medicine at the University of Melbourne and then completed his physicians training at the Austin Hospital as well as his PhD under Dr George Jerums and Professor Austin Doyle in the University of Melbourne, Department of Medicine, Austin Hospital. Dr Cooper has successfully competed for a large number of peer reviewed grants over the last 15 years from a range of organizations including not only JDRF but also the National Health & Medical Research Council of Australia, National Institutes of Health, National Heart Foundation of Australia, Diabetes Australia and Kidney Health Australia. In 1999, Dr Cooper was awarded the Eric Susman prize from the Royal Australasian College of Physicians for his research in the field of renal and vascular complications of diabetes. In 2005, he was awarded the Australian Diabetes Society (ADS) Kellion Award for outstanding contribution to diabetes research in Australia. In 1999, he was awarded a Centre Grant from JDRF which was subsequently renewed in 2003. He is a previous recipient of a scholars award from the JDRF. This work was further supported by a 5 year Australia Fellowship awarded by NHMRC in 2009. Dr Cooper is currently Co-Chair of the JDRF Medical Science Review Committee (Complications Panel). He is regularly invited to international meetings and has over 500 peer reviewed publications. Dr Cooper was the 2016 recipient of the Claude Bernard Award from the European Association for the Study of Diabetes and in 2017 the Edwin Bierman Award from the American Diabetes Association. He received an Order of Australia (Officer) in 2017. |
Petra Denig
|
Petra Denig is professor of Drug Utilization Quality in The Netherlands and head of the Research Section of the Clinical Pharmacy and Pharmacology Department at the University Medical Center Groningen. Major research aims are developing innovative strategies and insights that contribute to optimal use of medicines in practice from clinician and patient perspective. The focus is on chronic and complex diseases, particularly cardiovascular diseases and diabetes. Petra is leader of the Groningen Initiative to Analyse Type 2 diabetes Treatment (GIANTT) project, hosting a research database with longitudinal data obtained during routine care from >35.000 patients with type 2 diabetes. Petra and her co-workers have published around 100 peer-reviewed papers about prescribing behaviour, drug preferences, medication adherence, educational interventions, and treatment outcomes in real-world settings.
|
Ron Gansevoort
|
Prof. Ron T. Gansevoort is nephrologist, working in the Dept. of Nephrology at the University Medical Center Groningen, the Netherlands. He has two lines of research: the epidemiology of chronic kidney disease (CKD) and prevention of renal function loss in patients with heritable polycystic kidney disease (PKD). He is coordinator of the PREVEND study, an observational general population based study, investigating the association between albuminuria and health outcomes, and member of the Steering Committee of the international CKD Prognosis Consortium. He was instrumental in the work that led to the new KDIGO classification of CKD, for which he was awarded the United States Kidney Foundation Distinguished International Medal. Prof. Gansevoort also is head of the Groningen Expertise Centre for PKD. He is member of the Steering Committee of several international randomised controlled clinical trials in the field of PKD as well as diabetic nephropathy. Prof. Gansevoort is editor for 5 international nephrological journals, published over 400 peer-reviewed papers and supervised 20 PhD theses.
|
Maria Gomez
|
Maria F. Gomez is Professor of physiology at the Department of Clinical Sciences, Lund University and Director of the LUDC (Lund University Diabetes Centre; (http://www.ludc.med.se), with some of the best characterized clinical studies in diabetes and ~300 staff members working towards improved diagnosis, prevention and treatment of diabetes. The LUDC is considered one of the largest and most dynamic diabetes research centres in the world (http://www.ludc.med.lu.se/news-archive/scientific-grade-in-world-class-commendation-and-resumed-confidence/). After medical school, Dr. Gomez completed her Ph.D. in physiology at Lund University, Sweden in 1998. She then completed post-doctoral studies on calcium-dependent transcription in the laboratory of Dr. Mark T. Nelson, at the Pharmacology Department, University of Vermont. For the past 16 years her laboratory has focused on excitation-transcription coupling and mechanisms leading to macro- and microvascular complications of diabetes, with the aim to discover new targetable signaling pathways and develop new medicinal products. Dr. Gomez also coordinates IMI2 project BEAt-DKD (Biomarker Enterprise Attacking Diabetic Kidney Disease), a unique public private partnership focused on identifying drug targetable disease pathways and biomarkers of disease progression and treatment response in patients with DKD. She was scientific coordinator of efforts leading to the generation of several novel animal models of diabetic complications that better replicate human disease during IMI1 project SUMMIT (2009-2015). She has published ~100 scientific contributions and supervised 9 PhD theses, 7 post-docs and more than 30 undergraduate/masters students.
|
Hiddo Heerspink
|
Hiddo Lambers Heerspink is affiliated with the Department of Clinical Pharmacy and Pharmacology of the University Medical Center Groningen, the Netherlands. He received his PhD degree from the medical faculty of the University Medical Center Groningen in 2008. He then worked as a post-doctoral fellow at The George Institute in Sydney, Australia where he investigated the effects of blood pressure lowering regimens on renal and cardiovascular outcomes in patients with renal impairment. Based on this work, he was awarded a young investigator grant and subsequently in 2015 a consolidator investigator grant from the Dutch organisation of scientific research. Since 2010, Doctor Lambers Heerspink has held a position as a Clinical Pharmacologist at the University Medical Center Groningen. He is currently Professor Clinical Trials and Personalized Medicine. His main research interests include optimising treatment strategies and finding new therapeutic approaches to halt the progression of renal and cardiovascular disease. His particular clinical research interest is to identify determinants of individual treatment responses and ways to optimize drug response in individual patients. To achieve these goals he is involved in various international clinical trials and uses biomarkers and imaging techniques to unravel pathways and determinants of therapy response.
|
Meg Jardine
|
Prof Meg Jardine is a clinical researcher at The George Institute for Global Health. She is supported by a co-funded Australian National Health and Medical Research Council Career Development Fellowship and National Heart Foundation Future Leader Fellowship. She is Head of George Clinical Renal Trials, Deputy Director of the Renal Division of The George Institute, a Conjoint A/Professor of Medicine at The University of UNSW, Honorary A/Professor at The University of Sydney, Deputy Chair (Chair Elect) of the Australasian Kidney Trials Network (AKTN) and a practising nephrologist at Concord Repatriation General Hospital, a University of Sydney teaching hospital. Her research has focussed on investigating the progression and complications of kidney disease and diabetes through epidemiological analyses of large scale datasets and the use of innovative and cost-effective research methodologies.
|
Paul de Jong
|
Paul E de Jong is emeritus professor in Nephrology at the University of Groningen, the Netherlands. From 1993 till 2011 he was Professor in Nephrology and Head of Nephrology of the University Medical Center in Groningen. In 1996 he initiated the Prevention of Renal and Vascular End-stage Disease (PREVEND) study.
|
Jos Kosterink
|
Pharm.D, Ph.D, hospital pharmacist, clinical pharmacologist,University Medical Center Groningen, The Netherlands
In 2001 Jos G.W. Kosterink (1959) became head of the Department of Hospital and Clinical Pharmacy at the University Medical Center Groningen (UMCG), since June 2014 known as the Department of Clinical Pharmacy and Pharmacology. He still maintains this position. In 2005 he obtained his PhD-degree from the University of Groningen on the thesis “Strategies for specific drug targeting to tumor cells; Radiolabelled monoclonal antibodies from clone to clinic. He is also trained as a clinical pharmacologist. In July 2011 he is appointed Professor in Hospital Pharmacy/Clinical Pharmacy at the University Medical Center Groningen. He will combine this with his position as head of the department of Clinical Pharmacy and Pharmacology of the UMCG and a position in the department of Pharmacy of the Faculty of Science and Engeneering. His scientific interests include translational research of biopharmaceuticals (monoclonal antibodies and peptides), targeted and personalized medicine and investigating the added value of pharmacotherapeutic and pharmaceutical innovations. Professor Kosterink is (co)author of more than 100 peer-reviewed publications. He is currently supervising 10 PhD projects. His professional activities reach further than the hospital and he has been and still is very active in several (inter)national and regional boards, committees and working groups (eg board of the Netherlands Society of Hospital Pharmacists, Scientific advisory Board National Health Care Institute, the Netherlands Organisation for Health Research and Development (Pharmacotherapy), Competent Authority Specialisms of Pharmacy, Central Committee on Research involving Human Subjects, board Netherlands Pharmacovigilance Centre Lareb, EAHP-CTF). |
Matthias Kretzler
|
Dr. Kretzler is the Warner-Lambert/Parke-Davis Professor of Internal Medicine/Nephrology and Computational Medicine and Bioinformatics. The overarching goal of his research is to define kidney disease in mechanistic terms and use this knowledge for targeted therapeutic interventions. To reach this goal he has developed a translational research pipeline centered on integrated systems biology analysis of renal disease. He leads the U54 Nephrotic Syndrome Research Network (Neptune) in the Rare Disease Clinical Research Network II, the Data Visualization and a Tissue Interrogation Network in the NIDDK Kidney Precision Medicine Project and the Coordinating center of the CureGN research network. He is the Director of the Applied Systems Biology Core, principle investigator in the R24 “Integrated Systems Biology Approach to Diabetic Microvascular Complications”. He initiated and leads the Renal Precompetitive Consortium (RPC2) for precompetitive systems biology driven therapeutic target identification. He has 20 years of experience in integration of bioinformatics, molecular and clinical approaches in more than 250 papers and holds patents for diagnostic and therapeutics of chronic renal disease. He has a tract record on interdisciplinary data integration of large-scale data sets in international multi-disciplinary research networks in the US, Europe, China and sub-Saharan Africa. These studies enable precision medicine across the genotype-phenotype continuum using carefully monitored environmental exposures, genetic predispositions, epigenetic markers, transcriptional networks, proteomic profiles, metabolic fingerprints, digital histological biopsy archive and prospective clinical disease characterization. The molecular mechanism identified have result in new disease predictors and successful clinical trials of a novel therapeutic modalities in glomerular diseases.
|
Bert Leufkens
|
Dr Leufkens is professor of Pharmaceutical Policy and Regulatory Science at Utrecht University. During the mid-80s he worked at Leiden University and was a Fulbright Fellow at the University of Minnesota (US). In 1997 he was appointed as full professor at Utrecht University. From 2003-2005 he was the Scientific Director of the Utrecht Institute for Pharmaceutical Sciences (UIPS), and during 2006-2007 head of the Department of Pharmaceutical Sciences of the Faculty of Science in Utrecht. Dr Leufkens is research and policy-wise active at several (inter)national platforms on drug safety, pharmaceutical policy and regulatory science (e.g. past-member EMA Pharmacovigilance Working Party 2005-2009, chair of Dutch Medicines Evaluation Board (MEB) 2007-2017, past-member of the EMA CHMP 2009-2015, past-President of ISPE, since 2008 Scientific Director of the Utrecht WHO Collaborating Centre for Pharmaceutical Policy and Regulation. He is affiliate professor at the Faculdade de Farmácia da Universidade de Lisboa and the Copenhagen Centre for Regulatory Science (CORS). He is (co) author of >500 papers in peer reviewed journals, book chapters and research reports.
|
Adeera Levin
|
Dr Levin is a Professor of Medicine, Head Division of Nephrology at the University of British Columbia, and Consultant nephrologist at Providence Health Care/ St Paul’s Hospital, in Vancouver Canada. She is the Executive Director of the BC Renal Agency, which oversees the care, planning and budgets for Kidney services in the province of British Columbia. She is active in international activities across the spectrum of kidney activities, and has served as in leadership roles at the International Society of Nephrology (ISN), most recently as President ( 2015-17). She was one of the founding members of the Declaration of Istanbul Custodian Group (DICG), and served as one of the first Co-Chairs of that Group. She has been active in both ISN and DICG concerning advocacy for patient rights for equitqble access to care, and in the prevention of exploitation of vulnerable populations. Her major research interests include non traditional risk factors for CVD in CKD patients,( with particular focus on anemia, phosphate and vitamin D, and progression of CKD variability) as well as models of care. She has over 300 peer reviewed publications, and numerous book chapters, and is the inaugural Editor-in-Chief of the new Canadian Journal of Kidney Health & Disease. She is the Principal Investigator on a large cohort study CAN-PREDDICT, and more recently, a large national SPOR network grant CAN SOLVE CKD focusing on patient oriented research. She collaborates with investigators across Canada and internationally. She has received numerous teaching and research awards from local and national groups. In 2013, she was awarded the Canadian Society of Nephrology Outstanding Contributions to Canadian Nephrology, and 2014 was awarded the Kidney Foundation Research Medal of Excellence, and inducted as a fellow into the Canadian Academy of Health Sciences. In 2015 she was awarded the Aubrey J Tingle Research Award for contributions to the province of BC; and, for her contributions to the life of Canadians, she was awarded the Order of Canada in 2015.
|
James List
|
James F. List, M.D., Ph.D. is the Global Therapeutic Area Head of Cardiovascular & Metabolism (CVM), leading a global team focused on creating new solutions for improving cardiovascular and diabetes care. Jim has end-to-end research and development responsibility for the Janssen CVM portfolio, including drug discovery, clinical development, and external innovation. Jim joined Janssen in 2014. Prior to Janssen, Jim spent a decade at Bristol-Myers Squibb in roles of increasing responsibility. He most recently served as Vice President, Diabetes Development with responsibility for the diabetes joint venture alliance with AstraZeneca, overseeing development and alliance activities for multiple diabetes medicines. During his time at Bristol-Myers Squibb, he played a key role in formulating pipeline strategy and in the development of several diabetes medicines. Earlier in his career, he was a faculty member of Harvard Medical School with clinical responsibilities in General Endocrinology and Thyroid. Jim graduated from Stanford University and went on to complete his M.D. and Ph.D. from the University of Minnesota. He completed his medical training at Brigham and Women’s Hospital, Boston Children’s Hospital, and the Massachusetts General Hospital. Jim has been board certified in Internal Medicine, Pediatrics, and Endocrinology, and holds medical licenses in New Jersey and Massachusetts.
|
Fiona Loud
|
Fiona Loud has been Policy Director of Kidney Care UK (formerly known as the British Kidney Patient Association), the leading grant-giving charity supporting kidney patients in the UK, since 2013. She spent the previous 7 years as Director (previously Chair) of the Kidney Alliance, an umbrella organisation that brought together the main patient and professional charities in kidney care. She led and co-authored Kidney Health: Delivering Excellence, a kidney community review of kidney care 10 years after the National Service Framework was first launched. This work, with its ambitions for excellence in care from a patient and professional viewpoint, is supported by the Kidney Health Partnership of 7 key UK kidney charities. Fiona co-chairs the partnership. She is lay chair of the local Organ Donation Committee for West Hertfordshire Hospital Trust and a member of the NHS England Clinical Reference Group for renal services. She chairs the UK Renal Registry Patient Council. Fiona has been on a number of NICE Development and Topic Expert Groups including Chronic Kidney Disease (CKD) Quality Standards, Acute Kidney Injury and CKD Guidelines. In 2015 she became a Fellow of the British Renal Society and was one of the inaugural Health Service Journal top 50 patient leaders. Fiona spent 5 years on dialysis after her kidneys failed before receiving a transplant from her husband in late 2006. She has a degree in English from the University of Southampton. www.kidneycareuk.org @kidneycareUK
|
Johannes Mann
|
Johannes F. E. Mann, M.D., is currently full Professor of Medicine at the University of Erlangen-Nürnberg and Director, KfH Kidney Center, Munich-Schwabing, both in Germany. He is also International Scholar at Population Health Research Institute, McMaster University, Hamilton, ON, Canada. His previous assignments include Head, Dept. of Medicine, Munich General Hospitals, Staff member and Assistant Professor of Medicine, Dept. of Medicine, University of Heidelberg, Germany, and research fellowships in Pharmacology at the University of Montreal, Canada and at Heidelberg University, Germany.
Professor Mann, a board-certified specialist in Internal Medicine, in Nephrology, in Intensive Care and in Pharmacology and Toxicology, was an officer of the German Societies of Medicine and of the German Soc. of Nephrology, of the International Society of Nephrology and is on the editorial board of Kidney Intern., CJASN, and Clin. Nephrol. His scientific work concerns progression of renal disease, hypertension, the renin-angiotensin system as well as diabetic kidney disease. After experimental studies, he concentrated on clinical outcome trials in Nephrology including AIPRI (NEJM 1996), HOPE (NEJM, Lancet 2000), Renal-HOPE (Ann Int Med 2001), DIABHYCAR (BMJ 2004), ONTARGET (NEJM, Lancet 2008), Renal-TRANSCEND (Ann Int Med 2009), ASCEND (JASN 2010), STOP-JGA (NEJM 2015), LEADER (NEJM 2016), PURE (Lancet 2016). His work includes about 250 original papers. According to Lab Times his citations rank among the top 25 of European nephrologists. Some of his papers, published in Nature, NEJM, Lancet, JAMA and Ann Int Med, were cited more than 2500 times. |
Peter Mol
|
Assistant Professor at the University Medical Center Groningen. His research interest is in the area of regulatory science; from new tools to optimize regulatory decision-making to improving knowledge transfer with a specific interest in risk communication and medication safety. His key publications are on the impact of Direct Healthcare Professional Communications on drug utilization, regulatory decision-making and on various interventions to improve medication safety. Peter Mol participates in the IMI BEAT-DKD, where he co-leads Work Package 6 that seeks ways to optimize integration of new discoveries that aid personalization of diabetes therapy into the regulatory process. Further research projects are WEB-RADR focusing on patients’ and healthcare professionals’ views expectations of and views for two-way risk communication using a mobile app; SCOPE joint action on risk communication by National Competent Authorities; CORE2 on improving risk communication in hospital settings; cardio metabolic medication use in Sub Saharan Africa and usefulness of registries for regulatory purposes. Peter Mol is also a principal assessor at the Dutch Medicines Evaluation Board and a member (vice chair) of EMA’s Scientific Advice Working Party. He is chair of the EMA Cross-Committee Task force on Registries. He was vice-chair and cofounder of the Benefit Risk Assessment, Communication and Evaluation Special Interest Group (SIG) of the International Society of Pharmacoepidemiology (ISPE), cofounder of the risk communication SIG of the International Society of Pharmacovigilance (ISOP) and former executive committee member of the European Drug Utilisation Research Groups (EuroDURG).
|
Giuseppe Remuzzi
|
Giuseppe Remuzzi, M.D. – Bergamo, Italy. Director of the Division of Nephrology and Dialysis of the Papa Giovanni XXIII hospital (previous Ospedali Riuniti di Bergamo), “Chiara Fama” Professor of Nephrology at the University of Milan. He also directs the Negri Bergamo Laboratories of the “Mario Negri” Institute for Pharmacological Research, a group of basic scientists and clinicians devoted to the study of human renal diseases and their corresponding animal models from the perspective of pathophysiology and therapeutic intervention. He touched major advances in many areas of nephrology. For example, his studies have led to new insights into many disorders, including the interactions between platelets and endothelium, pathophysiology of glomerular diseases and the factors that influence the progressive loss of kidney function. Work focused on improving the outlook for patients with end stage renal disease. Giuseppe Remuzzi pays tribute to the work of pioneers such as Barry Brenner, who delved deep into the processes behind glomerular function and their possible reversibility. Early work on the use of angiotensin-converting enzyme inhibitors to slow the decline of glomerular filtration rates proved dialysis was avoidable, not inevitable. Studies on immunologic mechanisms that influence the survival of transplanted organs, understanding of immunologic tolerance in the disorders that are linked to autoimmunity and finally, genetic diseases of the kidney have also been areas of investigation. Concerned by kidney donation shortages and deploring the current practice of discarding suboptimal donor kidneys, his team has shown that transplanting such kidneys in pairs is feasible and have set up an international effort to validate this approach. Giuseppe Remuzzi is investigating the kidney's ability to regenerate itself. He authored and co-authored more than 1360 scientific articles, reviews and monographs and serves on editorial boards of numerous journals, he is member of the International Advisory Board of The Lancet and was Editorial Board member of the New England Journal of Medicine from 1995-2013. During his professional career he received the International Society of Nephrology (ISN) Jean Hamburger Award (World Congress of Nephrology (WCN) 2005, Singapore), the John P. Peters Award (American Society of Nephrology (ASN) 2007, San Francisco) and the ISN AMGEN Award (WCN 2011, Vancouver). In November 2011, he won the Third Edition of the International Award "Luis Hernando" assigned by the Iñigo Alvarez de Toledo Renal Foundation (FRIAT) in Madrid, Spain. From June 2013 till March 2015, he was President of the International Society of Nephrology (ISN).
|
Peter Rossing
|
Peter Rossing is a clinician researcher devoted to complications in diabetes with focus on renal and cardiovascular complications. He obtained a specialist degree in internal medicine and endocrinology 2004. Since 2007 he has been a chief physician and manager of the Steno Diabetes Center research team dedicated to the research of micro-and macrovascular complications of diabetes. Since 2012 Professor in diabetic angiopathy at University of Copenhagen. Peter Rossing has in epidemiological studies investigated key features of the pathophysiology of the diabetic kidney at different stages. He has identified several markers for development of diabetic nephropathy; making it possible to predict the individual risk. He has been involved in several intervention studies in patients with overt diabetic nephropathy aiming at improving the prognosis. He is coordinator of the EU FP7 project PRIORITY aiming to test if urinary proteomics can be used to stratify prevention of renal complications in type 2 diabetes, and the Novo Nordisk Foundation grant PROTON aiming at personalising prevention of diabetic nephropathy. He has co-authored >300 papers and his h-index is 57. He received the Minkowski prize in 2005 and the Golgi prize in 2016 both from the EASD. Past president of the Danish Endocrine Society, current president of the European Diabetic Nephropathy Study group and chairman of the Danish National Diabetes Registry
|
Shahnaz Shahinfar
|
Dr. Shahnaz Shahinfar is a research consultant to the pharmaceutical industry in drug development and the design and implementation of clinical trials. Throughout her career, she has been a member of various steering committees for compounds in development for renal disease. Her innovative work has resulted in numerous publications in peer-reviewed journals. Her clients have included Amgen, Johnson & Johnson, Bristol-Myers Squibb, Celgene, and Roche. Dr. Shahinfar launched her consultancy, S. Shahinfar Consulting, Inc., following a 23 year tenure at Merck, where she designed and led clinical trials in the areas of diabetes, hypertension, and kidney disease, including outcome trials. Her primary focus has been the progression of chronic kidney disease. While at Merck, she initiated and implemented the RENAAL trial, a landmark outcome study in type II diabetic patients with kidney disease. Dr. Shahinfar has also consulted on clinical trials of cardiovascular outcomes in patients with chronic kidney disease. She conducted some of the first double-blind, placebo-controlled, clinical trials in hypertensive children with enalapril, lisinopril, and losartan. Dr. Shahinfar received her medical degree from Ferdowsi University School of Medicine in Iran. She completed her Residency in Pediatrics, and Fellowship in Pediatric Nephrology, at Georgetown University Hospital in Washington, D.C. Currently, Dr. Shahinfar is an Adjunct Associate Professor of Pediatrics in the Associated Faculty of the School of Medicine at the University of Pennsylvania and the Children’s Hospital of Philadelphia.
|
Aliza Thompson
|
Aliza Thompson is a Clinical Team Leader in the Division of Cardiovascular and Renal Products, Center for Drug Evaluation and Research (CDER), at the U.S. Food and Drug Administration (FDA). Dr. Thompson joined the FDA in 2007; her team focuses on products being developed to treat renal-related indications. Dr. Thompson has served on several CDER biomarker qualification review teams and has been involved in larger efforts to define an evidentiary framework for CDER biomarker qualification. She received her medical degree from Johns Hopkins Medical School and completed her Internal Medicine and Nephrology training at Columbia University/New York-Presbyterian Hospital. She holds a Master of Science in Biostatistics/Patient Oriented Research Track from the Columbia University Mailman School of Public Health.
|
Vlado Perkovic
|
Vlado Perkovic is Executive Director of The George Institute, Australia, Professor of Medicine, UNSW Sydney and a Staff Specialist in Nephrology at the Royal North Shore Hospital. His research focus is in clinical trials and epidemiology, in particular in preventing the progression of kidney disease and its complications. He leads several major international clinical trials, serves on the Steering Committees of several others, and has led the development of George Clinical, the global clinical trials arm of The George Institute. He has been involved in developing Australian and global guidelines in kidney disease, cardiovascular risk assessment and blood pressure management. Vlado holds a Doctor of Philosophy from the University of Melbourne and completed his undergraduate training at The Royal Melbourne Hospital. He is a member of the National Health and Medical Research Council Principal Committee on Research Translation; is Chair of the International Society of Nephrology Action for Clinical Trials (ISN-ACT) group; and is a Fellow of the Royal Australasian College of Physicians, of the Australian Academy of Health and Medical Sciences and of the American Society of Nephrology
|
Maarten Postma
|
Prof Maarten J Postma (29/01/1960) holds the chair in Pharmacoeconomics at the University of Groningen (Netherlands). Also, he holds a chair in Global Health Economics at the University Medical Center Groningen (UMCG) and is director of UMCG’s research institute SHARE. He did his MSc in econometrics and his PhD in health economics. He specifically leads a team of 50 PhD and post-doc researchers in health- and pharmacoeconomics, contributing to many international research networks and scientific communications. Research areas comprise cost-effectiveness methods, for example, in vaccinology, transfusion science and personalized medicine. He serves (served) on various committees advising the Dutch government on reimbursement of drugs and vaccines (CVZ and Health Council). Also, he is advisor to various health-economics consultancy companies and pharmaceutical companies worldwide, Ministries of Health in neighbouring countries, member of editorial boards of scientific journals, on advisory boards for pharmaceutical companies and consultant for WHO. He is a member of UK’s Joint Committee of Vaccination & Immunization and advisor to the All Wales Medicines Strategy Group (Grwp Strategaeth Meddyginiaethau Gymru Gyfam). He is specialized in the role of pharmacoeconomics/health economics in the reimbursement process. He has over 350 MEDLINE-publications, an H-factor of 43 and extensive teaching/lecturing experience (Groningen, Heidelberg, Utrecht, Bielefeld, Ankara, Indonesia and Vietnam).
|